ZA201401968B - Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells - Google Patents
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cellsInfo
- Publication number
- ZA201401968B ZA201401968B ZA2014/01968A ZA201401968A ZA201401968B ZA 201401968 B ZA201401968 B ZA 201401968B ZA 2014/01968 A ZA2014/01968 A ZA 2014/01968A ZA 201401968 A ZA201401968 A ZA 201401968A ZA 201401968 B ZA201401968 B ZA 201401968B
- Authority
- ZA
- South Africa
- Prior art keywords
- tumours
- epithelial
- response
- kinase inhibitor
- tumour cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 230000011987 methylation Effects 0.000 title 1
- 238000007069 methylation reaction Methods 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542141P | 2011-09-30 | 2011-09-30 | |
| PCT/US2012/057777 WO2013055530A1 (en) | 2011-09-30 | 2012-09-28 | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201401968B true ZA201401968B (en) | 2018-05-30 |
Family
ID=47071458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/01968A ZA201401968B (en) | 2011-09-30 | 2014-03-18 | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130084287A1 (enExample) |
| EP (1) | EP2761025A1 (enExample) |
| JP (1) | JP2014531213A (enExample) |
| KR (1) | KR20140066783A (enExample) |
| CN (1) | CN104066851A (enExample) |
| AU (1) | AU2012321248A1 (enExample) |
| BR (1) | BR112014007569A2 (enExample) |
| CA (1) | CA2849120A1 (enExample) |
| IL (1) | IL231590A0 (enExample) |
| MX (1) | MX2014003698A (enExample) |
| RU (1) | RU2014110228A (enExample) |
| SG (1) | SG11201400996SA (enExample) |
| WO (1) | WO2013055530A1 (enExample) |
| ZA (1) | ZA201401968B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013082123A2 (en) * | 2011-11-28 | 2013-06-06 | University Of Chicago | Method, system, software and medium for advanced image-based arrays for analysis and display of biomedical information |
| AU2014274276A1 (en) * | 2013-05-31 | 2015-12-03 | Onconova Therapeutics, Inc. | Methods and compositions for predicting therapeutic efficacy of kinase inhibitors in patients with myelodysplastic syndrome or related disorders |
| CA2952390A1 (en) * | 2013-06-20 | 2014-12-24 | The Trustees Of The University Of Pennsylvania | Methods for diagnosing pancreatic cancer |
| US10233465B2 (en) * | 2013-11-04 | 2019-03-19 | Dow Agrosciences Llc | Optimal soybean loci |
| WO2016018087A1 (ko) * | 2014-07-29 | 2016-02-04 | 재단법인 아산사회복지재단 | Egfr-표적제제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도 |
| US20170356051A1 (en) * | 2014-10-17 | 2017-12-14 | Tohoku University | Method for estimating sensitivity to drug therapy for colorectal cancer |
| CN113981057A (zh) | 2014-12-12 | 2022-01-28 | 精密科学公司 | 用于进行甲基化检测测定的组合物和方法 |
| EP3230476B1 (en) | 2014-12-12 | 2020-02-05 | Exact Sciences Development Company, LLC | Zdhhc1 for normalizing methylation detection assays |
| EP3303626B1 (en) * | 2015-05-29 | 2020-04-01 | Vito NV | Epigenetic markers for respiratory allergy |
| WO2018009709A1 (en) * | 2016-07-06 | 2018-01-11 | Youhealth Biotech, Limited | Lung cancer methylation markers and uses thereof |
| TWI859118B (zh) * | 2017-03-29 | 2024-10-21 | 大陸商中美冠科生物技術（太倉）有限公司 | 測定對胃癌之西妥昔單抗（ｃｅｔｕｘｉｍａｂ）敏感性的系統及方法 |
| CN107144695B (zh) * | 2017-04-19 | 2019-02-26 | 南昌大学 | Arl13b蛋白在癌症诊断中的应用 |
| WO2018216009A1 (en) * | 2017-05-22 | 2018-11-29 | The National Institute For Biotechnology In The Negev Ltd. Ben-Gurion University Of The Negev | Biomarkers for diagnosis of lung cancer |
| CN110055313B (zh) | 2018-01-18 | 2024-03-08 | 纽克莱克斯有限公司 | 用于诊断肺癌的方法 |
| EP3775285B1 (en) * | 2018-06-15 | 2021-10-06 | Unilever IP Holdings B.V. | Epigenetic method to assess sun exposure |
| MX2021005963A (es) * | 2018-11-27 | 2021-08-24 | Exact Sciences Dev Co Llc | Caracterizacion de adn metilado, arn y proteinas en la deteccion de neoplasia pulmonar. |
| CN111521810B (zh) * | 2019-02-02 | 2024-06-21 | 中国科学院上海药物研究所 | 癌症患者根据脾酪氨酸激酶进行分层 |
| IL265451B (en) | 2019-03-18 | 2020-01-30 | Frumkin Dan | Methods and systems for the detection of methylation changes in DNA samples |
| CN110283910B (zh) * | 2019-06-21 | 2021-04-20 | 浙江大学 | 目标基因dna甲基化作为分子标志物在制备判别结直肠组织癌变进展试剂盒中的应用 |
| CN111304305B (zh) * | 2020-03-30 | 2023-05-30 | 陕西科技大学 | 一种用于检测egfr基因甲基化的试剂盒及方法 |
| CN111676286B (zh) * | 2020-05-29 | 2023-04-14 | 武汉爱基百客生物科技有限公司 | 肺癌血浆游离dna甲基化检测用的多重pcr引物系统、检测方法及应用 |
| CN114354927B (zh) * | 2021-03-18 | 2025-04-22 | 中国人民解放军陆军特色医学中心 | 唾液酸转移酶st3gal4作为egfr-tki耐药标志物的新应用 |
| CN115772565B (zh) * | 2021-09-08 | 2023-09-05 | 广州市基准医疗有限责任公司 | 用于辅助检测肺癌体细胞egfr基因突变的甲基化位点及其应用 |
| CN114525281B (zh) * | 2022-03-14 | 2024-03-12 | 右江民族医学院 | Esrp1启动子报告基因转录活性可视化及在去甲基化抗癌药物筛选中的应用 |
| CN115651984B (zh) * | 2022-10-20 | 2023-04-14 | 山东大学 | 一种生物标志物在评价肿瘤紫杉类化疗耐药性的应用 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| US6033854A (en) | 1991-12-16 | 2000-03-07 | Biotronics Corporation | Quantitative PCR using blocking oligonucleotides |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| WO1995006137A1 (en) | 1993-08-27 | 1995-03-02 | Australian Red Cross Society | Detection of genes |
| WO1995009647A1 (en) | 1993-10-07 | 1995-04-13 | The George Washington University Medical Center | METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN-α¿1? |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| DK0682027T3 (da) | 1994-05-03 | 1998-05-04 | Ciba Geigy Ag | Pyrrolopyrimidinderivater med antiproliferativ virkning |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| AU711592B2 (en) | 1995-04-03 | 1999-10-14 | Novartis Ag | Pyrazole derivatives and processes for the preparation thereof |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| DK0836605T3 (da) | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
| DK9500262U4 (da) | 1995-07-07 | 1996-10-07 | Bonus Energy As | Bundramme til vindmøllehus samt vindmølle omfattende samme |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| JP4275733B2 (ja) | 1996-01-23 | 2009-06-10 | ノバルティス アクチエンゲゼルシャフト | ピロロピリミジンおよびその製造法 |
| JP3406763B2 (ja) | 1996-01-30 | 2003-05-12 | 東レ・ダウコーニング・シリコーン株式会社 | シリコーンゴム組成物 |
| GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19629652A1 (de) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| EP0888353B1 (de) | 1996-03-15 | 2003-07-09 | Novartis AG | N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
| SK284073B6 (sk) | 1996-04-12 | 2004-09-08 | Warner-Lambert Company | Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze |
| GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| WO1997049688A1 (en) | 1996-06-24 | 1997-12-31 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| DE69718472T2 (de) | 1996-07-13 | 2003-11-06 | Glaxo Group Ltd., Greenford | Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| WO1998007726A1 (en) | 1996-08-23 | 1998-02-26 | Novartis Ag | Substituted pyrrolopyrimidines and processes for their preparation |
| JP4205168B2 (ja) | 1996-10-02 | 2009-01-07 | ノバルティス アクチエンゲゼルシヤフト | ピリミジン誘導体およびその製造法 |
| AU4779897A (en) | 1996-10-02 | 1998-04-24 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| US6329375B1 (en) | 1997-08-05 | 2001-12-11 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
| US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
| US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| KR20020000223A (ko) | 1999-05-14 | 2002-01-05 | 존 비. 랜디스 | 표피성장인자 수용체 길항제를 사용한 인간 난치성 종양의치료 방법 |
| US6180349B1 (en) | 1999-05-18 | 2001-01-30 | The Regents Of The University Of California | Quantitative PCR method to enumerate DNA copy number |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
| US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
| DE10130800B4 (de) | 2001-06-22 | 2005-06-23 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität |
| US20040132097A1 (en) | 2002-06-19 | 2004-07-08 | Bacus Sarah S. | Method for predicting response to epidermal growth factor receptor-directed therapy |
| CA2489360C (en) | 2002-06-26 | 2013-01-29 | Cold Spring Harbor Laboratory | Methods and compositions for determining methylation profiles |
| CA2506066A1 (en) | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Gene expression profiling of egfr positive cancer |
| EP1597558A2 (en) | 2003-01-08 | 2005-11-23 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| WO2004071572A2 (en) | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| JP4453297B2 (ja) | 2003-05-27 | 2010-04-21 | トヨタ自動車株式会社 | 車両用遊星歯車式多段変速機 |
| CA2527321A1 (en) | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| EP1664716A4 (en) | 2003-08-15 | 2008-08-13 | Smithkline Beecham Corp | CANCER BIOMARKERS |
| WO2006101925A2 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| ES2399075T3 (es) | 2006-08-30 | 2013-03-25 | Genentech, Inc. | Anticuerpos multiespecíficos |
| ES2628108T3 (es) | 2008-09-03 | 2017-08-01 | F. Hoffmann-La Roche Ag | Anticuerpos multiespecíficos |
| JP2012519281A (ja) * | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| WO2010099138A2 (en) * | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| JP2012524280A (ja) * | 2009-04-17 | 2012-10-11 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 上皮成長因子受容体キナーゼ阻害剤に対する抗がん反応を予測するための生物学的マーカー |
| US20140030255A1 (en) * | 2010-11-03 | 2014-01-30 | Merck Sharp & Dohme Corp. | Methods of predicting cancer cell response to therapeutic agents |
-
2012
- 2012-09-28 BR BR112014007569A patent/BR112014007569A2/pt not_active IP Right Cessation
- 2012-09-28 CN CN201280058401.1A patent/CN104066851A/zh active Pending
- 2012-09-28 JP JP2014533357A patent/JP2014531213A/ja active Pending
- 2012-09-28 US US13/630,363 patent/US20130084287A1/en not_active Abandoned
- 2012-09-28 CA CA2849120A patent/CA2849120A1/en not_active Abandoned
- 2012-09-28 AU AU2012321248A patent/AU2012321248A1/en not_active Abandoned
- 2012-09-28 RU RU2014110228/10A patent/RU2014110228A/ru not_active Application Discontinuation
- 2012-09-28 SG SG11201400996SA patent/SG11201400996SA/en unknown
- 2012-09-28 KR KR1020147011145A patent/KR20140066783A/ko not_active Ceased
- 2012-09-28 MX MX2014003698A patent/MX2014003698A/es unknown
- 2012-09-28 WO PCT/US2012/057777 patent/WO2013055530A1/en not_active Ceased
- 2012-09-28 EP EP12775890.2A patent/EP2761025A1/en not_active Ceased
-
2014
- 2014-03-18 ZA ZA2014/01968A patent/ZA201401968B/en unknown
- 2014-03-19 IL IL231590A patent/IL231590A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL231590A0 (en) | 2014-05-28 |
| JP2014531213A (ja) | 2014-11-27 |
| EP2761025A1 (en) | 2014-08-06 |
| US20130084287A1 (en) | 2013-04-04 |
| RU2014110228A (ru) | 2015-11-10 |
| WO2013055530A1 (en) | 2013-04-18 |
| KR20140066783A (ko) | 2014-06-02 |
| SG11201400996SA (en) | 2014-04-28 |
| AU2012321248A1 (en) | 2014-04-24 |
| MX2014003698A (es) | 2014-07-28 |
| BR112014007569A2 (pt) | 2017-04-18 |
| CA2849120A1 (en) | 2013-04-18 |
| CN104066851A (zh) | 2014-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL231590A0 (en) | Methylation markers diagnostic of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumors or cancer cells | |
| ZA201405140B (en) | Disubstituted benzothienyl-pyrolotriazines and their use as fgfr kinase inhibitors | |
| PL3111950T3 (pl) | Sposoby i kompozycje dotyczące antagonizmu receptora glukokortykoidów i nowotworu prostaty | |
| LT2556071T (lt) | Kinazės inhibitoriai ir jų panaudojimas vėžio gydymui | |
| EP2776837A4 (en) | COMBINATION OF KINASEINHIBITORS AND THEIR USE | |
| ZA201204793B (en) | Substituted naphthyridines and their use as syk kinase inhibitors | |
| GB201100180D0 (en) | Tumour cell and tissue culture | |
| EP2555801A4 (en) | SELECTION AND USE OF HOST CELLS FOR THE MANUFACTURE OF GLYCOPROTEINS | |
| ZA201404958B (en) | Mammalian fetal pulmonary cells and therapeutic use of same | |
| GB201200458D0 (en) | Methods of preparing cells and compositions | |
| ZA201406726B (en) | Methods and composition related to brown adipose-like cells | |
| PT2910567T (pt) | Mutante da quinase iii do ácido asparagínico, células hospedeiras e sua utilização | |
| SG11201502497RA (en) | Sebocyte cell culturing and methods of use | |
| ZA201503105B (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| IL245123A0 (en) | Short interfering RNA and its use in methods and preparations for preventing the expression of the orai1 gene | |
| IL237435A0 (en) | Methods for producing cells with a phenotype of primary human hepatocytes and composites | |
| ZA201400892B (en) | Detection of prame gene expression in cancer | |
| AU2016202399A1 (en) | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to EGFR kinase inhibitor in tumours or tumour cells | |
| EP2841556A4 (en) | COMPOSITIONS AND METHOD FOR MODULATING THE SENSITIVITY OF CELLS AGAINST AHAS INHIBITORS | |
| GB201209458D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201206048D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201112637D0 (en) | The process of nanostenting and nanomeshing cancer cells | |
| HK1228451A1 (en) | Sirna and their use in methods and compositions for inhibiting the expression of the pdk1 gene | |
| ZA201401878B (en) | Use of mad2l2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors |